Tony Nguyen

@weshowl @HH61USNO @InovioInvestor @RandPaul @marthamaccallum @FoxNews Lucky you to get An organic safe vaccine.

Joining @marthamaccallum on @FoxNews in just a few minutes to talk Fauci and more - tune in!

@InovioPharma Management need to step up and stop over promising time lines and not following through with simple updates. We work hard for our money and invest in a belief that you the company keep up your end. Very frustrated with how we are being treated.

Join INOVIO in taking an active role in the fight against cancer this #WorldCancerDay. Learn more about our clinical trials for #DNAMedicines aimed at preventing and treating specific cancers: bit.ly/3FPDcLe #WCD2022

@lijiang2087 @blitslabs You guys advertising this wallet so i downloaded and staked now i can not undelegate nor collect rewards. Customer service does not exist no phone number i messaged on twitter no replies yet.

can't wait for this to pop up on the app store! impressed by the @blitslabs team's execution.

@xuanloc20102001 @blitslabs Some kind of glitch but i have issues with this app i can not collect rewards or undelegate.

@blitslabs I staked but I can't see my asset in portfolio can you help me ?

🚨Remember Blits Wallet is a non-custodial wallet 🔑You never share your private keys so only you control your assets. #BlitsWallet $ONE

@InovioPharma @Nature_NPJ @CEPIvaccines

Our paper “INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants” was published in npj Vaccines. @Nature_NPJ Link: nature.com/articles/s4154…

@IvanDuque @InovioPharma @invimacolombia @CEPIvaccines

Nos reunimos con Joseph Kim, CEO de @InovioPharma, farmacéutica que el @invimacolombia autorizó para realizar ensayo clínico de la fase 3 de vacunas contra Covid en Colombia. Exploramos la firma de memorando de entendimiento para desarrollo y producción de biológicos en el país.

@CEPIvaccines Next-generation Pan-COVID-19 vaccine candidate, INO-4802, induced potent neutralizing antibodies and T cell responses against the original Wuhan strain as well as against B.1.1.7 (UK variant), B.1.351 (South African variant) and P.1. (Brazilian variant).

We've launched a $200million call to fund vaccines that are broadly protective against SARS-CoV-2 variants and other coronaviruses. The first partnerships to be made through this Call will be announced in the coming weeks⤵️ cepi.net/news_cepi/cepi…

As SARS-CoV-2 is one of seven known human coronaviruses—and more are likely to jump into the human population—a different approach to the current ‘one bug, one drug’ method is needed. Could we develop an all-in-one coronavirus vaccine?✍️@betswrites @WSJ wsj.com/articles/to-pr…

@CEPIvaccines next-generation Pan-COVID-19 vaccine candidate, INO-4802, induced potent neutralizing antibodies and T cell responses against the original Wuhan strain as well as against B.1.1.7 (UK variant), B.1.351 (South African variant

Our $3.5 billion plan aims to push the bounds of vaccine R&D to substantially reduce global epidemic and pandemic risk #EndPandemics ⬇️ endpandemics.cepi.net

@CEPIvaccines next-generation Pan-COVID-19 vaccine candidate, INO-4802, induced potent neutralizing antibodies and T cell responses against the original Wuhan strain as well as against B.1.1.7 (UK variant), B.1.351 (South African variant) and P.1. (Brazilian variant).

📢We've launched a new funding call to assess whether smaller doses of a #COVID19 vaccine booster shot—as opposed to a full dose—would improve, broaden, and prolong the immune response, while also helping to stretch global vaccine supplies. Find out more▶️bit.ly/3oShrWg

@CEPIvaccines @frekris @EU_ScienceHub next-generation Pan-COVID-19 vaccine candidate, INO-4802, induced potent neutralizing antibodies and T cell responses against the original Wuhan strain as well as against B.1.1.7 (UK variant), B.1.351 (South African variant) and P.1. (Brazilian variant) in preclinical models.

"CEPI chose to invest in a portfolio of diverse vaccines using both traditional and innovative technologies...A large portfolio increases our chances of developing many successful vaccines."💉 @frekris speaks to @EU_ScienceHub⏬ sciencemediahub.eu/2021/06/16/a-s…

@CEPIvaccines next-generation Pan-COVID-19 vaccine candidate, INO-4802, induced potent neutralizing antibodies and T cell responses against the original Wuhan strain as well as against B.1.1.7 (UK variant), B.1.351 (South African variant) and P.1. (Brazilian variant).

📢Our new funding Call will fund clinical trials evaluating the impact of reduced booster doses and third shots of #COVID19 vaccines. This approach could play an important role in stretching the global vaccine supply and increasing access to doses (1/6)➡️bit.ly/3lKZSph

@CEPIvaccines @BioCentury next-generation Pan-COVID-19 vaccine candidate, INO-4802, induced potent neutralizing antibodies and T cell responses against the original Wuhan strain as well as against B.1.1.7 (UK variant), B.1.351 (South African variant) and P.1. (Brazilian variant) .

What it will take to develop a vaccine in 100 days?⏱️ @BioCentury looks at the need for vaccine libraries soda machine-style manufacturing options, and some immunology lessons from the cancer field #EndPandemics⏬ biocentury.com/article/635224…

@CEPIvaccines @frekris @GloPID_R next-generation Pan-COVID-19 vaccine candidate, INO-4802, induced potent neutralizing antibodies and T cell responses against the original Wuhan strain as well as against B.1.1.7 (UK variant), B.1.351 (South African variant) and P.1. (Brazilian !!!!

Increased investment in ongoing vaccine R&D efforts will enable COVAX to deliver on its promises and ensure that our vaccines remain safe and effective against the emerging SARS-CoV-2 strains. ✏️ @frekris in @GloPID_R ⬇️ cepi.net/news_cepi/furt…

@CEPIvaccines @DrRHatchett @Corriere @viviana_mazza INOVIO's Pan-COVID-19 vaccine to induce cross-reactive immune responses against current and emerging viral variants as either a first-line vaccine, or potentially as a boost for individuals previously immunized with various Wuhan-matched vaccines.

“Now we're producing large quantities of vaccines and starting to straighten inequalities in distribution, there's the need to invest in research” @DrRHatchett speaks to @Corriere about defeating #COVID19 and preparing for the future ✏️@viviana_mazza⏬ corriere.it/esteri/21_otto…